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Abstract 
Background  
Conventional cardiopulmonary exercise testing (CPET) can objectively measure 
exercise intolerance, but cannot provide comprehensive evaluation of physiology. 
This requires additional assessment of cardiac output (CO) and arterio-venous 
oxygen content difference (a-vO2). We developed magnetic resonance (MR) 
augmented CPET (MR-CPET) to achieve this goal and assessed children with right 
heart disease.  
Methods and Results 
Healthy controls (n=10) and children with pulmonary arterial hypertension (PAH) 
(n=10) and repaired Tetralogy of Fallot (ToF) (n=10) underwent MR-CPET. All 
exercise was performed on a MR-compatible ergometer and oxygen uptake (VO2) 
was continuously acquired using a modified metabolic cart. Simultaneous CO was 
measured using a real-time MR flow sequence and combined with VO2 to calculate a-
vO2. Peak VO2 was significantly lower in the PAH group (12.6±1.31 ml/kg/min, 
p=0.01) and trended towards lower in the ToF group (13.5±1.29 ml/kg/min, p=0.06) 
compared to controls (16.7±1.37 ml/kg/min). Although ToF patients had the largest 
increase in CO, they had lower resting (3±1.2 l/min/m2) and peak (5.3±1.2 l/min/m2) 
values compared to controls (resting 4.3±1.2 l/min/m2, peak 6.6±1.2 l/ min/m2) and 
PAH patients (resting 4.5±1.1 l/min/m2, peak 5.9±1.1 l/min/m2). Both the PAH and 
ToF patients had blunted exercise induced increases in a-vO2. However, only the 
PAH patients had significantly reduced peak values (6.9±1.3 mlO2/100ml) compared 
to controls (8.4±1.4 mlO2/100ml, p= 0.005).  
Conclusions  
MR-CPET is feasible in both healthy children and children with cardiac disease. 
Using this novel technique we have demonstrated abnormal exercise patterns in 
VO2, CO and a-vO2. 
Key Words: exercise physiology; cardiovascular magnetic resonance imaging; 
tetralogy of Fallot; pulmonary hypertension; pediatric 
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Exercise intolerance is a common feature of cardiac disease and measurement of 
oxygen consumption (VO2) allows objective evaluation of exercise capacity. Studies 
have shown that peak VO2 is highly prognostic1 and cardiopulmonary exercise 
testing (CPET) is now routinely performed in these patients2.  
 
However, it does not provide a comprehensive assessment of physiology, as this 
also requires measurement of cardiac output (CO) and tissue oxygen (O2) extraction. 
These metrics can be assessed using invasive CPET (I-CPET), in which pulmonary 
and systemic arterial catheterisation is combined with exercise testing3. Using I-
CPET it is has been shown that tissue O2 extraction is reduced in pulmonary 
hypertension4 and this novel finding demonstrates the utility of the technique.  
 
Unfortunately, I-CPET is not practical in many patients groups due to its invasive 
nature. We have recently demonstrated an alternative non-invasive approach, which 
combines real-time MR flow assessment with MR compatible respiratory gas 
analysis5. The simultaneous acquisition CO and VO2 allows subsequent calculation 
of arterio-venous oxygen content difference (a-vO2)2, a recognized measure of O2 
extraction. Thus, MR augmented CPET (MR-CPET) provides a novel non-invasive 
method of comprehensively assessing exercise intolerance.  
  
The primary aim of this proof of concept study was to demonstrate the feasibility of 
MR-CPET in a pediatric population. In children, MR-CPET is particularly appealing 
as invasive CPET is challenging in this population. A secondary aim was to explore 
differences in VO2, CO and a-vO2 during exercise in children with right heart disease.  
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Methods  
Study population 
Thirty children divided into 3 groups were recruited into the study between February 
2015 and February 2016. Group 1 (n=10; 6 female) were healthy pediatric controls 
recruited specifically for this study with no suspected or previous past medical 
history. Group 2 (n=10; 7 female) were children with a diagnosis of stable PAH with 
no recent changes in medication. Group 3 (n=10; 4 female) children had a primary 
diagnosis of ToF repaired in infancy with current pulmonary regurgitation.  
 
General exclusion criteria were i) age <7 years, ii) MR incompatible implant, iii) 
physical or intellectual disability and iv) exercise induced collapse in the preceding 6 
months v) previously documented desaturation on exercise, vi) non-trivial tricuspid 
regurgitation. Specific group 2 exclusion criteria were: i) WHO functional class IV and 
ii) continuous intravenous therapy. The study was undertaken with national research 
ethics committee approval (National Health Service Health Research Authority; 
UKCRN ID 17282) and full written consent was obtained for all subjects.  
 
Six minute walk test 
All participants completed a six-minute walk test following the American Thoracic 
Society guidelines6 by a single operator (NB). 
 
MR-CPET 
Magnetic resonance augmented CPET was performed on a 1.5 Tesla MR scanner 
(Avanto, Siemens Medical Solutions, Erlangen, Germany) using two six-element 
body-matrix coils. The scanning room was temperature controlled and full pediatric 
resuscitation facilities and resuscitation team were available. ECG was continuously 
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monitored using the Siemens MRI vectorcardiogram (Siemens Medical Solutions, 
Erlangen, Germany).  
 
MR techniques – Cardiac output was assessed by measuring aortic flow at the level 
of the sino-tubular junction. Flow measurements were continuously acquired during 
exercise using a previously validated real-time UNFOLDed-SENSE spiral PCMR 
sequence5,7. Parameters were as follows: field of view=450 mm, matrix=160×160, 
voxel size=2.8×2.8×7 mm, TR/TE=5.8/1.4 ms, flip angle=20°, velocity encoding 
(VENC)=250 cm/s, R=6, temporal resolution=35 ms. The UNFOLDed-SENSE 
reconstruction was performed 'online' using a GPU-equipped external computer 
(Tesla C2070, Nvidia, Santa Clara, CA, USA) that was networked to the native 
scanner reconstruction system8. 
 
Ventricular volumes and septal curvature were assessed on a short axis stack using 
a previously validated real-time radial k-t SENSE steady state free precession 
sequence. The parameters used were: field of view=320 mm, matrix=128x128, voxel 
size 2.5x2.5x8, TR/TE= 2.4/1.17ms, flip angle=47°, R=8, temporal resolution=36ms.  
 
Respiratory gas analysis - Breath-by-breath gas exchange was analysed using a 
commercial CPET system (Ultima, MedGraphics, St. Paul, USA) equipped with an 
ele tro-galvanic oxygen sensor, a non-dispersive infrared carbon dioxide sensor and 
a calibrated differential pressure flow sensor. As the analyser was not MR 
compatible, it was placed in the control room and a modified MR compatible set of 
sampling tubes (umbilicus) were passed through the wave-guide (Figure 1) and 
attached to the patient via a pneumotach and facemask (Hans Rudolph, Kansas City, 
USA). The primary modifications to the umbilicus were increased length (470 cm 
compared to the standard 234 cm) and removal of ferromagnetic parts (see data 
supplement for full description of modifications). This customised umbilicus was 
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extensively tested by the manufacturer and met all of the normal quality control 
standards (data supplement). Gas and flow calibrations were performed before each 
patient was tested. All measures were taken at body temperature ambient pressure. 
 
Exercise Protocol  
Exercise was performed on a supine MR compatible ergometer (MR Cardiac 
Ergometer Up/Down, Lode, Groningen, The Netherlands) as shown in figure 1. This 
ergometer uses an up-down pedaling motion with the thighs relatively immobilized 
with straps. All participants underwent a standardized preparation protocol involving 
a verbal explanation, demonstration video and practice exercise prior to going into 
the scanner. Before starting the exercise protocol resting ventricular volumes were 
assessed. The exercise protocol consisted of a 1-minute rest period followed by 2 
minutes of unloaded exercise (figure 2) and the  a stepped workload protocol 
(increase of 2 Watts/minute for the first five minutes and subsequently 3 
Watts/minute until exhaustion). Ergometry was undertaken in hyperbolic mode and 
participants were encouraged to maintain revolutions per minute between 40 and 70 
to ensure workload was independent of cadence. During the exercise protocol CO 
and VO2 were continuously measured. At the point of exhaustion, resistance was 
reduced to zero and the subject was asked to exercise as hard as possible in order 
to maintain a high heart rate and prolong the exercise state. During this period, 
ventricular volumes (peak exercise) were assessed again (acquisition approximately 
30 seconds).  
 
Image analysis  
All images were processed using in-house plug-ins for the open-source software 
OsiriX (OsiriX Foundation, Geneva, Switzerland)9. Flow data was processed as 
previously described8. All magnitude images (up to 25000 frames) were segmented 
using a registration-based segmentation algorithm10 with manual operator correction 
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(see data supplement for full description of flow analysis). The resultant raw flow 
curves and VO2 data were further analysed using Matlab (Matlab 2012). The flow 
curves were automatically split into separate heart beats as previously described5 
(data supplement) and the stroke volume (SV) was calculated by integration. The 
heart rate (HR) and SV data were combined to calculate CO (HR x SV). Arterio-
venous oxygen content gradient (a-vO2) was then calculated as VO2/CO.   
 
For ventricular volumetric assessment, end systolic and diastolic frames were 
identified by visual assessment. Manual segmentation allowed measurement of right 
ventricular (RV) and left ventricular (LV) end diastolic volume (EDV) and end systolic 
volume (ESV). The stroke volume (SV) was the difference between these two values 
and ejection fraction (EF) was SV/EDV. As subjects with tricuspid regurgitation were 
excluded, it was possible to assess pulmonary regurgitation fraction (PRF) indirectly 
as: [(RVSV-LVSV)/RVSV)x100]. 
 
Septal curvature was measured from the short axis images at the mid-papillary 
level11. Raw curvature was taken as the inverse of the radius of the circle that was 
circumscribed by 3 points placed in the septum and propagated to all frames. The 
raw curvature was normalized using the lateral wall curvature and the minimum 
septal curvature ratio was taken as the lowest or most negative value.  
 
MR-CPET experience questionnaire 
Participants were asked to rate their experience of MR-CPET on a five-point Likert 
scale: (i) degree of concern prior to the test (1=very intense concern, 3=moderate, 
5=no concern), (ii) comfort during the test (1=very poor, 3=moderate, 5=very good), 
and (iii) degree of perceived helplessness (1=very intense helplessness, 
3=moderate, 5=no helplessness). Responses ≥3 were considered clinically 
acceptable.  
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Statistical Analysis  
All statistical analysis was performed using StataSE 13.0 (StataCorp, College 
Station, USA). Data were examined for normality using the Shapiro-Wilk normality 
test and non-normally distributed data was transformed using a log transform to 
ensure normal distribution prior to analysis. Descriptive statistics were expressed as 
mean (±standard deviation) or geometric mean (±geometric standard deviation) 
where data was log transformed for skewness. Between group differences were 
assessed using one-way analysis of variance (ANOVA) with post-hoc Bonferroni 
corrected pairwise comparisons. Differences in absolute metrics with exercise in 
different groups were assessed using repeated measures ANOVA with main effects 
of disease type and exercise and an interaction term representing disease multiplied 
by exercise. Greenhouse-Geisser epsilon for all the repeated measures models was 
calculated to assess sphericity and in all cases it equaled 1. Post-hoc pairwise 
comparisons were performed for simple main effects with Bonferroni correction and 
these are the p values reported in the results when comparing groups. Inter and intra 
observer variability was tested using intraclass correlation coefficients. Likert scale 
data was compared using the Kruskal Wallis test and gender distribution compared 
using Fisher’s exact test. A p-value <0.05 was considered statistically significant.  
 
Results
Demographics 
The mean age of the overall study population was 12.45±2.58 years with ToF 
patients being slightly older (p=0.03) than the PAH group (table 1). There were no 
significant group differences in height, weight or body surface area (table 1).  
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All PAH patients had idiopathic disease with 6/10 patients in functional class I and 
4/10 patients in class II. Eight subjects had undergone right heart catheterization in 
the 2 years preceding the study (median time 9.1 months, range 6.4-17.9 months). 
The average mean pulmonary arterial pressure was 37.2±12.1 mmHg and 
pulmonary vascular resistance index was 9.6±5.0 WU.m2. All patients were treated 
with either targeted mono or dual therapy; Bosentan: 9/10, Sildenafil: 8/10, Tadalafil: 
2/10, Amlodipine: 6/10, Ambrisentan: 1/10 and inhaled Iloprost: 2/10. In the repaired 
ToF patients, 9/10 were functional class 1 and 1/10 functional class II. The median 
age of primary surgery was 0.78 years (range 0.4-1.7 years) and 7/10 had 
transannular patch placement during their primary repair. Secondary surgical or 
catheter right ventricular outflow tract interventions had not been performed in any 
patients.  
 
There were no significant (p=0.71) differences in mean six-minute walk test distances 
between the control (444±1.1m), PAH (429±1.2) or ToF groups (449±1.1).  
 
Feasibility and Acceptability  
All recruited subjects successfully mastered the exercise technique and safely 
completed the MR-CPET protocol with no premature suspension of exercise. Cardiac 
output and VO2 data was collected in all subjects allowing calculation of a-vO2 in all 
cases. A r presentative example of the image data is shown in figure 3 and the 
processed data in figure 4.  
 
All subjects exercised to exhaustion achieving a peak respiratory exchange ratio 
(RER = VCO2/VO2)≥1.1. Healthy children achieved approximately 72% predicted 
heart rate, which was significantly higher than the PAH (62%, p<0.001) and ToF 
groups (56%, p<0.001). There were trends towards longer exercise duration and 
greater Watts achieved in the control group compared to the PAH and ToF groups 
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(table 2).  
 
There were no recorded complications (including documented arrhythmia) 
associated with exercise. All subjects reported clinically acceptable levels of 
satisfaction, comfort, worry and helplessness (table 2). There were no significant 
differences in these measures between groups (p>0.3).  
 
MR CPET metrics – Rest and Exercise 
At rest, there was no significant difference in VO2 between the groups (fig re 5, table 
3). At peak exercise VO2 increased 4.1±1.3x in controls, which was significantly 
greater than the increase in ToF (3.2±1.2x, p=0.04) and PAH (2.9±1.3x, p=0.01) 
patients. These differences resulted in peak VO2 being lower in the PAH group 
(12.6±1.31 ml/kg/min, p=0.01) and trending towards lower in the ToF group 
(13.5±1.29 ml/kg/min, p=0.06) compared to controls (16.7±1.37 ml/kg/min). 
 
Resting CO was significantly (p<0.001) lower in ToF patients compared to controls 
and PAH patients (figure 5, table 3). In PAH patients augmentation of CO was non-
significantly lower (1.3±1.3x) than in controls (1.6±1.3x, p=0.174) and peak CO only 
trended (p=0.1) towards being lower (table 3). Augmentation of CO was greater in 
ToF patients (1.8±1.3x) than controls, but did not reach significance (p=0.217). Due 
to the lower baseline CO, peak CO was still significantly lower in ToF patients 
(5.3±1.2 vs. 6.6±1.2, p=0.003). 
 
The ToF group had significantly higher a-vO2 (4.7±1.2 mlO2/100ml) at rest compared 
to the PAH (3.0±0.34 mlO2/100ml, p=0.001) and control groups (3.1±0.76 
mlO2/100ml, p=0.003). There was no significant difference in a-vO2 augmentation 
between controls (2.7±0.5x) and PAH patients (2.3±0.6x, p=0.18). Nevertheless, 
peak a-vO2 was lower in the PAH patients (6.9±1.3 mlO2/100ml vs. 8.4±1.4 
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mlO2/100ml, p=0.005). Conversely, a-vO2 augmentation was significantly lower in 
ToF patients (1.9±0.3x, p=0.001) compared to controls. However, due to the higher 
baseline value there was no significant difference (p=0.57) in peak a-vO2 (table 3). 
 
 
Ventricular volumes – Rest and Exercise 
Resting RVEDV, RVESV and RVSV were higher in the ToF group compared to 
controls (p<0.03). In all groups, RVEDV and RVESV decreased significantly by a 
similar amount with exercise (table 4). RVEF increased during exercise in all groups 
(table 4) but only reached significance in the PAH group (p=0.01).  
 
At rest, there were no group differences in LVEDV, LVESV, LVSV and LVEF (table 
4). At peak exercise, LVEDV fell significantly in controls (p=0.004) and PAH patients 
(p=0.006) but not in ToF patients. LVESV also fell at peak exercise but only reached 
significance in the control (p=0.002) and PAH groups (p=0.013). LVSV only 
increased significantly during exercise in the ToF group (p=0.035). In all groups, 
LVEF was significantly higher at peak exercise (table 4).  
 
Other metrics – Rest and Exercise 
Non-trivial PR was only present in the ToF group and at peak exercise PRF fell 
significantly in this group (p<0.001). Abnormal septal curvature was only present at 
rest (table 3) in the PAH group with significant worsening during exercise (p<0.001). 
This corresponds to an estimated mean PA pressure (mPAP) of 30±0.4mmHg at 
rest, rising to 55±0.53mmHg at peak exercise.  
 
Intra and Inter-observer reliability  
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There was good intraobserver reliability in real time CO data (ICC 0.995, 95% CI 
0.98–0.999 p<0.001). There was also good interobserver reliability (ICC 0.996, 95% 
CI 0.983–0.999 p<0.001).  
 
 
 
 
Discussion  
This proof of concept study demonstrates the feasibility of MR-CPET in children with 
cardiovascular disease. The main findings of our study were i) MR-CPET was safe in 
healthy children and those with right heart disease, ii) peak VO2 was reduced in 
pediatric PAH and ToF patients and iii) PAH and ToF patients had different peak 
values and patterns of augmentation of CO and a-vO2 compared to controls.  
 
MR CPET findings  
In this study, we recruited relatively well patients in whom there was no significant 
difference in 6MWT distance compared to controls. Nevertheless, PAH patients had 
reduced peak VO2 and ToF patients had a trend towards lower peak VO2. This is in 
keeping with previous studies in relatively well patients12,13 and demonstrates the 
sensitivity of conventional CPET for assessing mild exercise intolerance. Using MR-
CPET, we were also able to demonstrate significant differences between the groups 
that weren’t apparent with VO2 alone. For example, PAH patients had a slightly 
blunted CO response to exercise and a trend towards lower peak CO. On the other 
hand, ToF patients had reduced resting and peak CO despite a slightly amplified CO 
response to exercise. The findings in the PAH patients are unsurprising, but the 
findings in ToF patients are unexpected and warrant further explanation. It is 
conventionally believed that resting CO is preserved in ToF patients until late in the 
disease. Thus, our findings may simply be an artifact of non-representative sampling. 
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Still there are some CMR studies that suggests CO is lower in pediatric ToF patients 
when compared to normal children (assessed in a separate study but by the same 
group)14,15. These studies would seem to strengthen the validity of our resting 
findings, but larger studies are still required for further corroboration. The slightly 
better augmentation of CO in ToF patients is the result of increased effective RVSV 
due to a fall in PR 16. However, peak CO is still lower in ToF patients (due to the 
lower baseline value) and this might have important consequences for exercis  
tolerance.  
 
Our MR-CPET data also allows evaluation of differences in tissue oxygen extraction 
(as assessed by a-vO2). Our results demonstrate a blunted response to exercise in 
PAH patients, which resulted in lower peak tissue oxygen extraction. Similar findings 
have been demonstrated in adults with PAH using I-CPET4, but the exact cause is 
unclear. Biopsy studies have demonstrated skeletal muscle abnormalities in animal 
and human models of PAH including reduced capillary density17,  changes in ratio of 
muscle fiber type18 and alter tions in mitochondrial function19. Such changes could 
be the cause of reduced peak tissue oxygen extraction in these patients. Tissue 
oxygen extraction could also be affected by the vasodilator therapy, which was 
universal in our population. Possible mechanisms for this are intramuscular shunting 
and direct effects on muscle/mitochondrial physiology. Therefore, it would by useful 
to evaluate tissue oxygen extraction on a vasodilator naïve population in a future 
study.  
 
Children with repaired ToF also had abnormal patterns of tissue oxygen extraction. 
The higher resting a-vO2 in ToF patients could simply due to mathematical coupling 
between a CO and VO2, although it may have physiological relevance. The ToF 
patients also had a significantly blunted increase in a-vO2, although they reached a 
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similar peak to controls. Further work is required to understand if and how these 
abnormalities impact on exercise tolerance.  
 
We believe that these results demonstrate that MR-CPET allows incremental 
improvement in understanding of exercise dysfunction. Specifically, it provides 
insights not available if CO and VO2 are measured alone. Similar data is also 
available using invasive CPET, which has the added benefit of providing 
simultaneous assessment of pulmonary artery pressure. This is pertinent in PAH 
patients because exercise induced increase in pulmonary artery pressure may be a 
useful clinical biomarker20. Unfortunately, invasive CPET is difficult to perform in 
children, as general anesthesia is usually required to perform cardiac catheterization. 
Consequently, MR-CPET may be useful as a substitute in the pediatric population, 
as well as in other groups.  
 
One finding that has not been previously described is worsening septal curvature in 
PAH during exercise. It has been shown that septal curvature (measured using MR) 
correlates strongly with resting mPAP in children with PAH21. Our results suggest that 
mPAP increases significantly during exercise in this group. This is consistent with 
invasive studies in adults20, but has not been shown in children due to the difficulties 
in performing exercise catheterization in this age group. The ability to non-invasively 
assess pulmonary hemodynamics during exercise has several clinical uses. These 
include unmasking borderline PAH patients, assessing exercise induced pulmonary 
hypertension and investigating the causes of unexplained exercise intolerance.  
  
Feasibility and Safety 
In this study, all exams were completed safely with no arrhythmia or exercise 
induced complications. This is unsurprising as conventional CPET has been shown 
to be safe in these patient groups13,22 and we only chose to study functional class 1 
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and 2 children. However, full 12-lead ECG monitoring is not readily available in MR 
and this does prevent the use of MR-CPET in patients with significant risk of 
ischemia or arrhythmia. It was possible to obtain a continuous single lead ECG 
during exercise in children unlike our previous adult study5 in which ECGs were non-
interpretable. We believe that superior quality of the ECG signal in children was due 
to less movement during exercise and consequently less motion artifacts. Of course, 
for MR-CPET to become a useful clinical tool it is vital that a universal and robust 
solution to monitoring electrical activity is developed.  
 
 
 
Technical considerations 
Although real-time techniques are invaluable when performing exercise CMR, there 
are concerns over reduced image quality and robustness. Real-time MR techniques 
have been extensively tested against conventional gated MR with good agreement23. 
In addition, a recent study has demonstrated good agreement between SV assessed 
using real-time MR volumes an  the direct Fick method during exercise24. Thus, we 
believe that real-time MR is a valid method of evaluating physiology during exercise. 
Furthermore, recent innovations in real-time MR post-processing such as pseudo-
cardiac and respiratory gating24 and improved automated segmentation10 may also 
improve measurement fidelity.  
 
A further complication in this study was the need to continuously measure flow in 
order to guarantee acquisition of data at peak exercise. The resultant data consisted 
of up to 25,000 frames of flow images, representing a massive reconstruction and 
post-processing problem. We used an online GPU reconstruction system8 to ensure 
that data was available in a clinically meaningful time. Currently there are no 
commercial software solutions that can handle this amount of data and consequently 
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we had to use an in-house post-processing tool. Even using this optimized system, 
data analysis was time consuming and could take several hours with operator 
adjustments. One method of reducing total processing time is to only segment the 
data at rest and around the point of exhaustion. This takes approximately 30 minutes 
and the reduced time makes MR-CPET more feasible in the clinical environment. 
Reducing the amount of image segmentation might also enable data to be more 
easily processed on commercial software. This is vital as the inability to process data 
using validated and quality controlled software is a major limitation of this technique 
and an impediment to dissemination. One disadvantage of only processing a portion 
of the data is that the ‘shape’ of the full VO2, CO and a-vO2 curves may be clinically 
important. We have not explored the shape of these curves in the current study, but 
this is an important area for future research.  
 
We used a standard clinical CPET system that was made MR compatible by a simple 
and inexpensive modification to the umbilicus. Other studies have made similar 
modifications (with removal of ferromagnetic parts) to commercially available gas 
analysis systems to make them MR compatible25. Importantly even though these 
modifications resulted in increased dead space, there was no significant 
measurement difference compared to an unmodified system. Another possible 
solution is to adapt the fully MR-compatible gas analysis systems for monitoring of 
patients under general anesthesia. These systems are not validated for exercise, but 
do suggest a future direction for development.  
 
Limitations 
The main limitation of this study is that although the subjects exercised until 
exhaustion with satisfactory RERs, the exercise performed was sub-maximal. 
Performing normal rotary exercise in the confined space of a MR scanner is difficult. 
Therefore, we used an up-down ergometer that requires a swimming-like, rather than 
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cycle-like motion. Unfortunately, this type of motion uses fewer muscle groups than 
cycling partially explaining the significantly lower power output achieved in this study 
compared to conventional CPET. In addition, peak VO2 and SV augmentation are 
consistently found to be lower at peak supine exercise compared to upright exercise 
in both adults and children26,27,8,28. Thus, our form of supine exercise cannot be 
directly compared to conventional CPET and this must be taken into consideration 
when interpreting the results. Nevertheless, we have previously demonstrated a 
good correlation between peak VO2 obtained during MR-CPET and conventional 
CPET. Consequently, we believe that peak VO2 measured during MR-CPET is still a 
good marker of exercise capacity.  
 
Another possible cause of these findings is abnormal pulmonary reserve, which was 
not formally tested in this study. It is known that these patient groups do exhibit 
abnormalities in lung function29 and the efore, it would be important to evaluate this 
in future studies.  
 
The ergometer used in this study is also heavy and may in the case of obese adults 
and adolescents exceed the recommended weight limit of the MRI table. Thankfully, 
a wide range of alternative commercial ergometers with more acceptable dimensions 
are available30-32 and could be used for MR-CPET. 
 
Conclusions  
This proof of concept study demonstrates the innovative use of an integrated MR-
CPET approach both in healthy children and children with cardiac disease. Using this 
novel non-invasive methodology, we were able to show significant differences in the 
exercise responses in our patient groups. The technique is potentially of wider utility 
in cardiovascular disease, particularly when symptoms are induced or exacerbated 
by exercise.  
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Clinical Perspective  
This study demonstrates the feasibility and safety of an innovative combined 
magnetic resonance augmented cardiopulmonary exercise test (MR-CPET) in non-
invasively assessing exercise physiology in children with cardiovascular disease.  
Reduced exercise capacity is a common feature of cardiovascular disease and is 
recognised to be prognostic in several conditions. This novel technique was able to 
demonstrate distinct patterns of oxygen consumption, cardiac output and 
arteriovenous oxygen concentration gradient in patients with pulmonary hypertension 
and tetralogy of Fallot compared to healthy controls. Importantly, it provides 
significantly more information than magnetic resonance assessment of the 
cardiovascular system alone. We believe that MR-CPET provides a more 
comprehensive assessment of abnormal physiology during exercise and will enable 
better understanding of exercise dysfunction. In the future, this might allow better 
identification and management of exercise intolerance with the development of 
patient specific treatments.  
 
 
References  
 Di
scl
aim
er:
 Th
e m
anu
scr
ipt
 an
d it
s c
on
ten
ts a
re
con
fid
ent
ial,
 int
end
ed 
for
 jou
rna
l re
vie
w p
urp
ose
s
     
     
 on
ly, 
and
 no
t to
 be
 fu
rth
er 
dis
clo
sed
.
 18
1. Cahalin LP, Chase P, Arena R, Myers J, Bensimhon D, Peberdy MA, Ashley 
E, West E, Forman DE, Pinkstaff S, Lavie CJ, Guazzi M. A meta-analysis of 
the prognostic significance of cardiopulmonary exercise testing in patients with 
heart failure. Heart Fail Rev. 2013;18:79–94.  
2. Balady GJ, Arena R, Sietsema K, Myers J, Coke L, Fletcher GF, Forman D, 
Franklin B, Guazzi M, Gulati M, Keteyian SJ, Lavie CJ, Macko R, Mancini D, 
Milani RV, American Heart Association Exercise, Cardiac Rehabilitation, and 
Prevention Committee of the Council on Clinical Cardiology, Council on 
Epidemiology and Prevention, Council on Peripheral Vascular Disease, 
Interdisciplinary Council on Quality of Care and Outcomes Research. 
Clinician's Guide to cardiopulmonary exercise testing in adults: a scientific 
statement from the American Heart Association. Circulation. 2010;122:191–
225.  
3. Berry NC, Manyoo A, Oldham WM, Stephens TE, Goldstein RH, Waxman AB, 
Tracy JA, Leary PJ, Leopold JA, Kinlay S, Opotowsky AR, Systrom DM, 
Maron BA. Protocol for exercise hemodynamic assessment: performing an 
invasive cardiopulmonary exercise test in clinical practice. Pulmonary 
Circulation. 2015;5:610–618.  
4. Tolle J, Waxman A, Systrom D. Impaired systemic oxygen extraction at 
maximum exercise in pulmonary hypertension. Medicine & Science in Sports 
& Exercise. 2008;40:3–8.  
5. Barber NJ, Ako EO, Kowalik GT, Steeden JA, Pandya B, Muthurangu V. MR 
augmented cardiopulmonary exercise testing—a novel approach to assessing 
cardiovascular function. Physiological Measurement. 2015;:85–94.  
6. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care 
Med. 2002;166:111–117.  
7. Kowalik GT, Knight DS, Steeden JA, Tann O, Odille F, Atkinson D, Taylor A, 
Muthurangu V. Assessment of cardiac time intervals using high temporal 
resolution real-time spiral phase contrast with UNFOLDed-SENSE. Magn 
Reson Med. 2015;73:749–756.  
8. Kowalik GT, Steede  JA, Pandya B, Odille F, Atkinson D, Taylor A, 
Muthurangu V. Re l-time flow with fast GPU reconstruction for continuous 
assessment of cardiac output. J Magn Reson Imaging. 2012;36:1477–1482.  
9. Rosset A, Spadola L, Ratib O. OsiriX: an open-source software for navigating 
in multidimensional DICOM images. J Digit Imaging. 2004;17:205–216.  
10. Odille F, Steeden JA, Muthurangu V, Atkinson D. Automatic segmentation 
propagation of the aorta in real-time phase contrast MRI using nonrigid 
registration. J Magn Reson Imaging. 2011;33:232–238.  
11. Real-Time Magnetic Resonance Assessment of Septal Curvature Accurately 
Tracks Acute Hemodynamic Changes in Pediatric Pulmonary Hypertension. 
Circ Cardiovasc Imaging. 2014;7:706–713.  
12. Mahle WT, McBride MG, Paridon SM. Exercise performance in tetralogy of 
Fallot: the impact of primary complete repair in infancy. Pediatr Cardiol. 
2002;23:224–229.  
 Di
scl
aim
er:
 Th
e m
anu
scr
ipt
 an
d it
s c
on
ten
ts a
re
con
fid
ent
ial,
 int
end
ed 
for
 jou
rna
l re
vie
w p
urp
ose
s
     
     
 on
ly, 
and
 no
t to
 be
 fu
rth
er 
dis
clo
sed
.
 19
13. Abumehdi MR, Wardle AJ, Nazzal R, Charalampopoulos A, Schulze-Neick I, 
Derrick G, Moledina S, Giardini A. Feasibility and safety of cardiopulmonary 
exercise testing in children with pulmonary hypertension. Cardiol Young. 
2015;26:1144–1150.  
14. Sarikouch S, Koerperich H, Dubowy K-O, Boethig D, Boettler P, Mir TS, 
Peters B, Kuehne T, Beerbaum P, German Competence Network for 
Congenital Heart Defects Investigators. Impact of gender and age on 
cardiovascular function late after repair of tetralogy of Fallot: percentiles based 
on cardiac magnetic resonance. Circ Cardiovasc Imaging. 2011;4:703–711.  
15. Sarikouch S, Peters B, Gutberlet M, Leismann B, Kelter-Kloepping A, 
Koerperich H, Kuehne T, Beerbaum P. Sex-specific pediatric percentiles for 
ventricular size and mass as reference values for cardiac MRI: assessment by 
steady-state free-precession and phase-contrast MRI flow. Circ Cardiovasc 
Imaging. 2010;3:65–76.  
16. Lurz P, Muthurangu V, Schuler PK, Giardini A, Schievano S, Nordmeyer J, 
Khambadkone S, Cappeli C, Derrick G, Bonhoeffer P, Taylor AM. Impact of 
reduction in right ventricular pressure and/or volume overload by 
percutaneous pulmonary valve implantation on biventricular response to 
exercise: an exercise stress real-time CMR study. European Heart Journal. 
2012;33:2434–2441.  
17. Potus F, Malenfant S, Graydon C, Mainguy V, Tremblay È, Breuils-Bonnet S, 
Ribeiro F, Porlier A, Maltais F, Bonnet S, Provench r S. Impaired 
angiogenesis and peripheral muscle microcirculation loss contribute to 
exercise intolerance in pulmonary arterial hypertension. Am J Respir Crit Care 
Med. 2014;190:318–328.  
18. Batt J, Shadly Ahmed S, Correa J, Bain A, Granton J. Skeletal Muscle 
Dysfunction in Idiopathic Pulmonary Arterial Hypertension. Am J Respir Cell 
Mol Biol. 2013;50:74-86.  
19. Enache I, Charles A-L, Bouitbir J, Favret F, Zoll J, Metzger D, Oswald-
Mammosser M, Geny B, Charloux A. Skeletal muscle mitochondrial 
dysfunction precedes right ventricular impairment in experimental pulmonary 
hypertension. Mol Cell Biochem. 2013;373:161–170.  
20. Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. 
Exercise-Induced Pulmonary Arterial Hypertension. Circulation. 
2008;118:2183–2189.  
21. Pandya B, Moledina S, McKee A, Schulze I-N, Muthurangu V. Analysis of the 
septal curvature with CMR in the paediatric population with pulmonary 
hypertension is a useful tool. Journal of Cardiovascular Magnetic Resonance. 
2012;14:P83.  
22. Rhodes J, Tikkanen AU, Jenkins KJ. Exercise Testing and Training in Children 
With Congenital Heart Disease. Circulation. 2010;122:1957–1967.  
23. Setser RM, Fischer SE, Lorenz CH. Quantification of left ventricular function 
with magnetic resonance images acquired in real time. J Magn Reson 
Imaging. 2000;12:430–438.  
 Di
scl
aim
er:
 Th
e m
anu
scr
ipt
 an
d it
s c
on
ten
ts a
re
con
fid
ent
ial,
 int
end
ed 
for
 jou
rna
l re
vie
w p
urp
ose
s
     
     
 on
ly, 
and
 no
t to
 be
 fu
rth
er 
dis
clo
sed
.
 20
24. La Gerche A, Claessen G, Van de Bruaene A, Pattyn N, Van Cleemput J, 
Gewillig M, Bogaert J, Dymarkowski S, Claus P, Heidbuchel H. Cardiac MRI A 
New Gold Standard for Ventricular Volume Quantification During High-
Intensity Exercise. Circ Cardiovasc Imaging. 2013;6:329–338.  
25. Lafountain RA, da Silveira JS, Varghese J, Mihai G, Scandling D, Craft J, 
Swain CB, Franco V, Raman SV, Devor ST, Simonetti OP. Cardiopulmonary 
exercise testing in the MRI environment. Physiological Measurement. 
2016;37:N11–N25.  
26. Koga S, Shiojiri T, Shibasaki M, Kondo N, Fukuba Y, Barstow TJ. Kinetics of 
oxygen uptake during supine and upright heavy exercise. J Appl Physiol. 
1999;87:253–260.  
27. May LJ, Punn R, Olson I, Kazmucha JA, Liu MY, Chin C. Supine Cycling in 
Pediatric Exercise Testing: Disparity in Performance Measures. Pediatr 
Cardiol. 2013;35:705–710.  
28. Frick MH, Somer T. Base-line effects on response of stroke volume to  leg 
exercise in the supine position. J Appl Physiol. 1964;19:639–643.  
29. Sun X-G, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary 
pulmonary hypertension. Journal of the American College of Cardiology. 
2003;41:1028–1035.  
30. Gusso S, Salvador C, Hofman P, Cutfield W, Baldi JC, Taberner A, Nielsen P. 
Design and testing of an MRI-compatible cycle ergometer for non-invasive 
cardiac assessments during exercise. Biomed Eng Online. 2012;11:13.  
31. Jeneson JAL, Schmitz JPJ, Hilbers PAJ, Nicolay K. An MR-compatible bicycle 
ergometer for in-magnet whole-body human exercise testing. Magn Reson 
Med. 2010;63:257–261.  
32. Pesta D, Paschk  V, Hoppel F, Kobel C, Kremser C, Esterhammer R, 
Burtscher M, Kemp GJ, Sch cke M. Different metabolic responses during 
incremental exercise assessed by localized 31P MRS in sprint and endurance 
athletes and untrained individuals. Int J Sports Med. 2013;34:669–675.  
  
 
 
 
 
 
 
 
 
 Di
scl
aim
er:
 Th
e m
anu
scr
ipt
 an
d it
s c
on
ten
ts a
re
con
fid
ent
ial,
 int
end
ed 
for
 jou
rna
l re
vie
w p
urp
ose
s
     
     
 on
ly, 
and
 no
t to
 be
 fu
rth
er 
dis
clo
sed
.
 21
 
 
 
 
 
 
 
 
 
 
Figure Legends 
Figure 1. MR-CPET set-up. This image demonstrates a volunteer using the MR-
compatible ergometer while inside the bore of the scanner. An optical interface cable 
(orange) passes from the control room through the wave-guide to control the 
ergometer. The modified MR-compatible umbilicus (white) also passes from the 
metabolic cart through the wave-guide and connects to the patient via a pneumotach 
and facemask.  
 
Figure 2. Schematic representation of the MR-CPET protocol.  
 
Figure 3. Examples of MR flow images subsets at rest and exercise throughout the 
cardiac cycle. 
 
Figure 4. Representative oxygen uptake (VO2) cardiac output (CO) and arterio-
venous oxygen content gradient  (a-vO2) curves for a high-performing individual 
volunteer from the control group (red line) and individual volunteers from the 
pulmonary arterial hypertension (pale blue line) and tetralogy of Fallot groups (purple 
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line). Combined VO2, CO and a-vO2  curves for all subjects are provided in the 
supplemental data section.  
 
Figure 5.  Changes in mean MR-CPET metrics between rest and peak exercise, in 
the control (continuous line) PAH (dashed line) and ToF (dotted line). Error bars 
represent SEM. There was no significant difference in resting oxygen uptake (VO2) 
but a lower peak VO2 in the PAH group than the control group (p=0.01). Note higher 
resting arterio-venous oxygen content gradient (a-vO2) in the ToF group with no 
significant difference at peak exercise and lower a-vO2 at peak exercise in the PAH 
group than the control group (p= 0.005).  
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Table 1. Demographics.  
Variable Control PAH ToF p-value 
Male:Female  4:6 3:7 6:4 0.53 
Age, years 13±3 11±2.2 14±1.8 0.033 
Height, cm*† 154±1.1 147±1.1 159±1.1 0.066 
Weight, kg*  47±1.5 41±1.3 50±1.4 0.432 
Body Surface Area m2† 1.5±0.38 1.3±0.17 1.5±0.29 0.145 
*Log transformed (geometric mean); † W test applied 
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Table 2. Exercise capacity and acceptability data. 
 
Variable Control PAH ToF p-value 
Six minute walk test distance, m*  452±1.1 432±1.2 449±1.1 0.718 
MR-CPET Exercise duration, min† 8.9±3 7.3±1.6 7±2.2 0.078 
Peak Work, Watts*† 12.0±2 8.7±1.5 7.7±1.9 0.145 
Peak Work, METS* 4.8±1.4 3.6 ± 1.3 3.8 ± 1.3 0.079 
Percept Predicted HR 72±8.2 62±9.6 56±8.1 <0.001 
RER† 1.7±0.43 1.5±0.28 1.4± 0.15 0.011 
Satisfaction  4.4±0.7 4.3±0.48 4.6±0.52 0.45 
Comfort* 3.5±1.3 3.5±1.3 3.8±1.2 0.82 
Helplessness* 3.7±1.4 4±1.2 4.4±1.2 0.35 
       
RER, respiratory exchange ratio; HR, heart rate; *Log transformed (geometric mean).† W test applied.  
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Table 3. MR-CPET derived measures.  
 
Variable Control PAH ToF p-value  
 Rest Peak Rest Peak Rest Peak Disease 
effect 
Time effect Disease-time 
interaction 
HR, bpm 83±17 149±18† 82±9.3 131±20† 74±12 116±17† <0.001 <0.001 <0.001 
SV, ml/m2 49±11 46±8.2 49±5.9 46±6.3 41±8.4 46±5.4 0.43 0.75 <0.001 
CO, l/m2/min* 4.3±1.2 6.6±1.2† 4.5±1.1 5.9±1.1† 3±1.2 5.3±1.2† <0.001 <0.001 0.0016 
VO2, ml/kg/min* 4.06±1.35 16.7±1.37† 4.32±1.18 12.6±1.31† 4.24±1.17 13.5± 1.29† 0.51 <0.001 0.011 
a-vO2, mlO2/100ml 
blood 
3.1±0.76 8.4±1.4† 3±0.34 6.9±1.3 † 4.7±1.2 8.7±1.5† <0.001 <0.001 0.013 
HR, heart rate, beats per minute; SV, stroke volume; CO, cardiac output; VO2, oxygen uptake; a-vO2, arterio-venous oxygen content gradient. *Log transformed (geometric 
mean). †significant difference rest to peak.  
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Table 4. Conventional MR derived measures. 
 
Variable Control PAH ToF p-value  
 Rest Peak Rest Peak Rest Peak Disease 
effect 
Time effect Disease-time 
interaction 
RV EDV, ml/m2 77±16 68±13† 83±9.2 71±9.1† 95±16 86±14† <0.001 <0.001 0.6 
RV ESV, ml/m2* 29±1.3 20±1.6† 34±1.3 28±1.3† 39±1.3 30±1.5† 0.041 <0.001 0.44 
RV SV, ml/m2 47±11 45±9.5 48±6.7 46±6.9 55±7.8 54±7.1 0.045 0.095 0.9 
RV EF, % 62±5 67±12 58±7.8 66±9.8† 58±6 63±8.6 0.59 <0.001 0.67 
LV EDV, ml/m2 67±13 59±9.6† 68±7.4 61±8.1† 63±5.2 64±6.2 0.87 <0.001 0.011 
LV ESV, ml/m2* 18±1.3 11±2† 20±1.2 14±1.4† 19±1.3 17±1.3 0.18 <0.001 0.14 
LV SV, ml/m2 48±9.9 47±7.2 48±6.7 47±7 43±6.1 46±5.5 0.55 0.59 0.024 
LV EF, % 72±5.5 80±11† 70±4.4 77±7.3† 68±7.1 73±5.9 0.17 <0.001 0.54 
PRF, % 0.48±1.0 0.29±0.89 1.11±1.47 0.14±0.43 30.24±8.03 16.3±5.79† <0.001 <0.001 <0.001 
Septal curvature 
ratio* 
0.84±0.05 0.82±0.08 0.15±0.42 -0.44±0.53 0.85±0.13 0.86±0.071 <0.001 <0.001 <0.001 
 
RV, right ventricle; LV, left ventricle; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume; EF, ejection fraction; PRF, pulmonary regurgitant fraction; mPA, 
estimated mean pulmonary arterial pressure. *Log transformed (geometric mean).†significant difference rest to peak.  
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